Latest Insider Transactions at Keros Therapeutics, Inc. (KROS)
This section provides a real-time view of insider transactions for Keros Therapeutics, Inc. (KROS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Keros Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Keros Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2024
|
Carl L Gordon Director |
SELL
Open market or private sale
|
Indirect |
250,000
-19.72%
|
$11,000,000
$44.01 P/Share
|
|
Aug 13
2024
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
250,000
-19.72%
|
$11,000,000
$44.01 P/Share
|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$1,800,000
$45.29 P/Share
|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$640,000
$16.0 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-71.87%
|
$920,000
$46.25 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-93.25%
|
$960,000
$48.16 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Apr 08
2023
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.56%
|
$0
$0.48 P/Share
|
|
Nov 29
2022
|
Tomer Kariv |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Ran Nussbaum |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
46,034
-32.62%
|
$1,381,020
$30.0 P/Share
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,034
+24.6%
|
$0
$0.3 P/Share
|
|
Jul 13
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,916
-1.97%
|
$57,480
$30.0 P/Share
|
|
Jul 13
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,916
+2.01%
|
$0
$0.3 P/Share
|
|
Jun 14
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,400
+9.0%
|
$0
$0.3 P/Share
|
|
Jun 09
2022
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.97%
|
$0
$0.3 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.18%
|
$227,900
$43.35 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.49%
|
$328,600
$62.84 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Apr 06
2022
|
Christopher Rovaldi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
1,728
-100.0%
|
$112,320
$65.0 P/Share
|
|
Apr 06
2022
|
Christopher Rovaldi CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,728
+50.0%
|
$27,648
$16.0 P/Share
|
|
Apr 04
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,950
-8.49%
|
$477,000
$60.0 P/Share
|
|
Apr 04
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,950
+7.82%
|
$0
$0.3 P/Share
|
|
Apr 01
2022
|
Christopher Rovaldi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
864
-45.57%
|
$48,384
$56.85 P/Share
|
|
Apr 01
2022
|
Christopher Rovaldi CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
864
+50.0%
|
$13,824
$16.0 P/Share
|
|
Mar 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-1.01%
|
$140,450
$53.44 P/Share
|
|
Mar 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+2.91%
|
$0
$0.3 P/Share
|
|
Feb 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-1.01%
|
$137,800
$52.32 P/Share
|
|
Feb 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+2.91%
|
$0
$0.3 P/Share
|
|
Jan 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-1.01%
|
$140,450
$53.34 P/Share
|
|
Jan 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+2.91%
|
$0
$0.3 P/Share
|
|
Jan 05
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,650
-3.0%
|
$159,000
$60.0 P/Share
|
|
Jan 05
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,650
+2.91%
|
$0
$0.3 P/Share
|
|
Jan 05
2022
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
4,034
-0.23%
|
$233,972
$58.14 P/Share
|
|
Jan 04
2022
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
20,062
-0.68%
|
$1,123,472
$56.97 P/Share
|
|
Jan 03
2022
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
23,555
-0.96%
|
$1,366,190
$58.25 P/Share
|
|
Dec 15
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
735
-0.85%
|
$36,750
$50.0 P/Share
|
|
Dec 15
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
735
+0.84%
|
$0
$0.3 P/Share
|
|
Dec 13
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,915
-0.73%
|
$97,665
$51.99 P/Share
|
|
Dec 13
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,915
+2.14%
|
$0
$0.3 P/Share
|
|
Dec 02
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
25,338
-0.98%
|
$1,342,914
$53.42 P/Share
|
|
Dec 01
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
22,313
-0.84%
|
$1,227,215
$55.03 P/Share
|
|
Nov 11
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-2.93%
|
$312,700
$59.25 P/Share
|
|
Nov 11
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Nov 10
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,900
-15.65%
|
$954,000
$60.0 P/Share
|
|
Nov 10
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,900
+13.53%
|
$0
$0.3 P/Share
|
|
Nov 04
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,600
-11.01%
|
$530,000
$50.0 P/Share
|